Syntho Pharmaceuticals
- Company typePrivate
- Founded1975
- HeadquartersLucknow, India
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Syntho Pharmaceuticals does
Syntho Pharmaceuticals Pvt. Ltd. is a privately held, founder-controlled specialty pharmaceutical company headquartered in Lucknow, Uttar Pradesh, that develops, manufactures, and commercializes branded ophthalmic products for the Indian market and generic ophthalmic formulations for export markets. The company operates a WHO GMP certified production plant with an independent QC section and ISO 9001:2015 certification, producing eye drops and ointments across antibiotics, corticosteroids, NSAIDs, lubricants, and anti-glaucoma categories under brands such as MOSS, THOMOXX, ATROCIN, DEXCIN, and Obra.
The company runs a sales-led go-to-market model in India, deploying a network of medical representatives targeting ophthalmologists in cities including Lucknow, Delhi, Haryana, Jaipur, Bikaner, and Jodhpur, supported by a claimed distribution network of 10,000+ distributors and a contact database of 15,000+ ophthalmologists. Internationally, Syntho ships generic ophthalmic drops and ointments through export houses, providing dossiers, Certificates of Analysis, and Certificates of Pharmaceutical Product (COPP) under USP and BP standards across markets spanning several countries.
The business makes money primarily through one-time sales of branded pharmaceutical SKUs at quote-based pricing, with no subscription, licensing, or recurring revenue model disclosed. Founded in 1975 by Mr. Dinesh Agarwal and led today by a family management team, Syntho has 45+ years of lineage, 11-50 employees, and no external institutional funding on record. The company's stated differentiators are regulatory compliance, distribution depth, and longevity in a specialized therapeutic category, rather than proprietary technology or differentiated pricing power.
Syntho Pharmaceuticals firmographics
Firmographics- Name
- Syntho Pharmaceuticals
- Legal name
- Syntho Pharmaceuticals Pvt. Ltd.
- Website
- https://eyepharma.in
- Company type
- Private
- Founded year
- 1975
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Syntho Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Ophthalmic & Otic Generics (HLAIABAF), Eye, Ear & Nasal Care (HLAIADAF)
Keywords
Where Syntho Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Lucknow
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Syntho Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Ophthalmic Pharmaceutical Products: Sale of branded pharmaceutical products for ophthalmology including eye drops and ointments through domestic distribution and export channels
- Export Products: Generic ophthalmic drops and ointments exported to several countries through export houses, with documentation including dossiers, Certificate of Analysis, and COPP
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pharmaceutical pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Syntho Pharmaceuticals product offering
Product offeringCore offering
Syntho Pharmaceuticals develops, manufactures, and commercializes branded ophthalmic pharmaceutical products including eye drops, eye ointments, and ear drops for the Indian domestic market, and exports generic ophthalmic and otic formulations to international markets through export houses. The product portfolio spans antibiotics, corticosteroids, NSAIDs, lubricants, glaucoma medications, and combination products, manufactured at a WHO GMP certified facility in Lucknow, India.
Product overview
Syntho Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing branded ophthalmic pharmaceutical products. The company's product portfolio consists of over 30 distinct eye and ear drop formulations and ointments sold in India, along with generic ophthalmic products for international export. The India market portfolio includes antibiotic formulations (ATROCIN, DEXCIN, Mycin, Ktromoxx), corticosteroid combinations (CORTECYCLINE, Obra-D, F-LONE), NSAID formulations (NSAID-N, Phenosulf), lubricant eye drops (MOSS family including MOSS, MOSS FRESH Gel, MOSS PG, MOSS PLUS), glaucoma treatments (Timo-5, THOMOXX, THOMOXX-L), and combination products (Mezol, NUGEN, OLOTAD, P-LONE, QUGAT, Phentrop, HY-MOSS). The company also exports generic ophthalmic formulations internationally under USP and BP standards. The portfolio spans multiple therapeutic categories including antibiotics, anti-inflammatory agents, lubricants, and glaucoma medications.
Differentiator
Problem solved
Functional benefit
Products and services
- ATROCIN P Eye Ointment Branded ophthalmic ointment formulation in the antibiotic category, sold through Syntho's domestic distribution network in India for treatment of eye conditions.
- ATROCIN Eye Ointment Branded ophthalmic ointment formulation in the antibiotic category for the Indian domestic market, distributed through Syntho's medical representatives and distributors.
- CORTECYCLINE Eye Ointment Branded ophthalmic ointment in the corticosteroid combination category for Indian domestic ophthalmic use.
- DEXCIN Eye & Ear Drops Combination ophthalmic and otic drop formulation in the antibiotic/corticosteroid category for Indian domestic treatment of eye and ear conditions.
- DEXCIN-M Eye Drops Branded ophthalmic combination drop formulation in the antibiotic/corticosteroid category, sold in India.
- F-LONE Eye Drops Corticosteroid ophthalmic drop formulation for the Indian domestic market for treatment of inflammatory eye conditions.
- HY MOSS Eye Drops Branded ophthalmic drop formulation in the HY MOSS / MOSS family for Indian domestic use.
- HY MOSS T Drops Newly launched branded ophthalmic drop formulation in the HY MOSS product family, sold in India.
- Ktromoxx Eye Drops Antibiotic ophthalmic drop formulation distributed in the Indian domestic market through Syntho's field force and distributors.
- LOW-DEX Eye & Ear Drops Corticosteroid ophthalmic and otic drop formulation for the Indian domestic market.
- Mezol Eye Drops Combination ophthalmic drop formulation sold in the Indian domestic market for treatment of multiple eye conditions.
- MOSS FRESH Gel Lubricant Eye Drops Gel-based lubricant eye drop in the MOSS family for dry eye relief, sold in India.
- MOSS Lubricant Eye Drops Lubricant eye drop formulation in the MOSS family for dry eye relief, sold in India.
- MOSS PG Lubricant Eye Drops Lubricant eye drop formulation in the MOSS family, distributed in India for dry eye conditions.
- MOSS PLUS Lubricant Eye Drops Lubricant eye drop formulation in the MOSS family for dry eye relief, sold in India.
- Mycin Eye Drops Antibiotic ophthalmic drop formulation in the Indian domestic market for treatment of bacterial eye infections.
- NS-AID Eye Drops NSAID ophthalmic drop formulation sold in India for inflammation-related eye conditions.
- NSAID-N Eye Drops NSAID ophthalmic drop formulation distributed in India.
- NUGEN Eye & Ear Drops Combination ophthalmic and otic drop formulation for the Indian domestic market.
- Obra-D Eye Ointment Ophthalmic ointment formulation in the Obra family for Indian domestic ophthalmic treatment.
- Obra Eye Drops & Ointment Ophthalmic drop and ointment combination product in the Obra family, sold in India.
- Obra-F Eye Drops Ophthalmic drop formulation in the Obra family sold in India.
- OLOTAD Eye Drops Combination ophthalmic drop formulation sold in India for treatment of eye conditions.
- P-LONE Eye Drops Corticosteroid ophthalmic drop formulation sold in India.
- Phenosulf Eye Drops NSAID ophthalmic drop formulation distributed in India.
- Phentrop Eye Drops Newly launched branded ophthalmic drop formulation sold in India.
- QUGAT Eye Drops Combination ophthalmic drop formulation sold in India.
- THOMOXX Eye Ointment Ophthalmic ointment formulation in the THOMOXX family for the Indian domestic market.
- THOMOXX Eye Drops Ophthalmic drop formulation in the THOMOXX family for the Indian domestic market.
- THOMOXX-L Eye Drops Newly launched ophthalmic drop formulation in the THOMOXX family for the Indian domestic market.
- Timo-5 Eye Drops Glaucoma treatment ophthalmic drop formulation (beta-blocker) sold in India.
- Calodin Eye Drops Branded ophthalmic drop formulation sold in India through Syntho's distribution network.
- Chloramphenicol Otic Solution 0.1% USP (Export) Generic antibiotic otic solution exported internationally under USP standards for treatment of ear infections.
- Chloramphenicol Eye Drops 0.5% USP (Export) Generic antibiotic ophthalmic drops exported internationally under USP standards for bacterial eye infections.
- Ciprofloxacin Eye Drops 3mg/ml USP (Export) Fluoroquinolone antibiotic ophthalmic drops exported under USP standards for bacterial eye infections.
- Clotrimazole Ear Drops 1% w/v (Export) Antifungal otic drops exported internationally for treatment of fungal ear infections.
- Dexamethasone 0.1% w/v & Chloramphenicol 1% w/v Eye Drops (Export) Combination corticosteroid and antibiotic ophthalmic drops exported internationally for inflammatory eye conditions complicated by bacterial infection.
- Dexamethasone Eye Drops 0.1% w/v (Export) Corticosteroid ophthalmic drops exported under USP standards for inflammatory eye conditions.
- Timolol Maleate Ophthalmic Solution 0.5% USP (Export) Beta-blocker ophthalmic drops exported under USP standards for treatment of glaucoma and ocular hypertension.
- Cromolyn Sodium Ophthalmic Solution USP 4% w/v (Export) Mast cell stabilizer ophthalmic drops exported under USP standards for treatment of allergic conjunctivitis.
- Chloramphenicol Ophthalmic Ointment USP 1% w/v (Export) Generic antibiotic ophthalmic ointment exported internationally under USP standards for eye infections.
- Tetracycline Eye Ointment 1% USP (Export) Generic antibiotic ophthalmic ointment exported under USP standards for bacterial eye infections.
- Prednisolone Sodium Phosphate Eye Drops BP 0.1% w/v (Export) Corticosteroid ophthalmic drops exported under BP standards for treatment of ocular inflammation.
- Betamethasone Ear Drops 0.1% (Export) Corticosteroid otic drops exported internationally for treatment of inflammatory ear conditions.
- Carboxymethyl Cellulose 1% (Export) Lubricant ophthalmic drops exported internationally for dry eye relief.
- Chloramphenicol Ear Drops 5% (Export) Generic antibiotic otic drops exported internationally for bacterial ear infections.
- Ciprofloxacin Eye Drops BP 0.2% w/v (Export) Fluoroquinolone antibiotic ophthalmic drops exported under BP standards.
- Moxifloxacin Ophthalmic Solution USP (Export) Fourth-generation fluoroquinolone ophthalmic drops exported under USP standards for bacterial eye infections.
- Tobramycin + Dexamethasone Eye Drops (Export) Combination antibiotic and corticosteroid ophthalmic drops exported internationally for inflammatory eye conditions with bacterial infection risk.
Companies that use Syntho Pharmaceuticals
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Syntho Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Syntho Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Delhi Ophthalmological Society (DOS)coreSyntho Pharmaceuticals participated as a supporter in the Delhi Ophthalmological Society Midterm Conference 2021 held on March 20-21, 2021 at Hotel Ashoka, New Delhi. The two-day event saw participation from ophthalmologists across India and abroad through online and offline sessions.
- Ophthalmological Societies Network (GSI, UPSOS, UKSOS, DOS, AIOS)minorActive involvement in knowledge sharing and development through various ophthalmological societies including Glaucoma Society of India (GSI), UP State Ophthalmological Society (UPSOS), UK State Ophthalmological Society (UKSOS), Delhi Ophthalmological Society (DOS), and All India Ophthalmological Society (AIOS).
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
Syntho Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Intas Pharmaceuticals: Large Indian pharmaceutical company with ophthalmic products spanning glaucoma, anti-infectives, and dry eye. Competes with Syntho for ophthalmologist share in India and generic ophthalmic exports.
- Entod Pharmaceuticals: India-based specialty pharmaceutical company focused exclusively on ophthalmology, ENT, and dermatology. Closely comparable as a smaller, specialty-focused Indian pharma with similar product categories (eye drops, ointments) and sales-led GTM via medical representatives.
- Centaur Pharmaceuticals: Indian pharmaceutical manufacturer with a dedicated ophthalmic division producing eye drops and ophthalmic preparations. Comparable as a domestic specialty player in the Indian ophthalmic market.
- Ajanta Pharma: Indian specialty pharmaceutical company with ophthalmology and ENT product lines. Competes in similar ophthalmic therapeutic categories and exports to multiple international markets through documentation similar to Syntho's dossier/COA/COPP approach.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company with a substantial ophthalmic franchise (Sun Pharma's ophthalmic division markets branded and generic eye drops and ointments). Direct competitor in Indian ophthalmic prescriptions and exports, with significantly larger scale and R&D budget.
- Micro Labs: Indian pharmaceutical manufacturer with ophthalmic and ENT product portfolios. Comparable as a domestic Indian generic ophthalmic manufacturer competing for ophthalmologist prescriptions and export tenders.
- FDC Limited: Indian pharmaceutical company with a meaningful ophthalmic and ENT product portfolio including eye drops and lubricants. Comparable as a domestic Indian manufacturer competing for ophthalmologist prescriptions and pharmacy distribution.
- Cipla: Major Indian pharmaceutical manufacturer with a significant ophthalmic product portfolio spanning antibiotics, anti-allergy, and glaucoma. Competes with Syntho in both Indian branded ophthalmics and international generic exports.
Broad incumbents
- Alcon: Global leader in eye care with a broad ophthalmic pharmaceutical and surgical portfolio. While significantly larger and focused on premium branded products, it competes indirectly with Syntho for ophthalmologist mindshare in India and serves as the innovation benchmark that domestic players chase.
- AbbVie (Allergan Aesthetics/eye care): Global pharmaceutical major whose Allergan acquisition brought a market-leading ophthalmic pharmaceutical portfolio (including Refresh, Lumigan, Alphagan). Competes indirectly in Indian ophthalmology through branded premium products and represents the global benchmark Syntho's generics are formulated against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Syntho Pharmaceuticals social profiles
Digital presenceSyntho Pharmaceuticals compliance and trust
Trust signalCompliance2 records
Syntho Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syntho Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Syntho Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syntho Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syntho Pharmaceuticals
What does Syntho Pharmaceuticals do?
Syntho Pharmaceuticals develops, manufactures, and commercializes branded ophthalmic pharmaceutical products including eye drops, eye ointments, and ear drops for the Indian domestic market, and exports generic ophthalmic and otic formulations to international markets through export houses. The product portfolio spans antibiotics, corticosteroids, NSAIDs, lubricants, glaucoma medications, and combination products, manufactured at a WHO GMP certified facility in Lucknow, India.
Is Syntho Pharmaceuticals a public or private company?
Syntho Pharmaceuticals is a private company. It is classified as family owned and is currently operating.
When was Syntho Pharmaceuticals founded?
Syntho Pharmaceuticals was founded in 1975. It employs 11 to 50 people.
Where is Syntho Pharmaceuticals based?
Syntho Pharmaceuticals is headquartered in Lucknow, India, in the Asia region.
How does Syntho Pharmaceuticals make money?
Two revenue lines are on record. Ophthalmic Pharmaceutical Products are the primary driver. The others are export Products.
Who are Syntho Pharmaceuticals's main competitors?
Direct peers on record are Intas Pharmaceuticals, Entod Pharmaceuticals, Centaur Pharmaceuticals, Ajanta Pharma, Sun Pharmaceutical Industries, Micro Labs, FDC Limited and Cipla. Broad incumbents are Alcon and AbbVie (Allergan Aesthetics/eye care).
Does Syntho Pharmaceuticals have an API?
No public API is recorded for Syntho Pharmaceuticals.
What industry is Syntho Pharmaceuticals in?
Syntho Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIABAF, Ophthalmic & Otic Generics. Its NAICS code is 325412 and its SIC code is 2834.